Pictor’s new product launch - here and in the U.S.
Further to my previous communications on Pictor, there have been some exciting developments across their human and animal health diagnostic products.
Further to
my previous communications on Pictor, there have been some exciting
developments across their human and animal health diagnostic products.
Proven success
Since the New Zealand launch, consumer feedback on the PictArray™
SARS-CoV-2 Antibody Test has demonstrated real clinical utility for both
doctors and patients. One particular patient said the test has “had
lifechanging results”.
Following an extended period of illness with suspected COVID-19 but
without having confirmation of infection using antigen or PCR tests, the
PictArray™ SARS-CoV-2 Antibody Test confirmed a previous infection with
the COVID-19 virus. This result has allowed the patient to engage with
their doctor around treatment and management as a potential Long-Covid
case.
Another patient’s PictArray™ SARS-CoV-2 Antibody Test showed they had
not generated protective antibodies in response to five doses of
COVID-19 vaccine due to a concurrent course of immunosuppressant
medication. Based on this result, the patient’s doctor prescribed
treatment with monoclonal antibodies to provide protection against the
COVID-19 virus that their immune system could not produce.
And here’s a recent article in NZ Doctor which says “The
PictArray™ SARS-CoV-2 assay is the first test of its kind. It enables
personalized COVID-19 assessments by detecting if a patient has
antibodies from a previous infection of SARS-CoV-2 – from spike protein
(SP) and nucleocapsid protein (NP) antibodies or from vaccination alone
(SP antibodies only).
“It indicates whether at-risk patients have failed to mount a
detectable antibody response despite vaccination or infection (SP and NP
negative)”.
Animal health
Within its Animal Health division, Pictor has commenced alpha trials for
their much-anticipated Johne’s disease test. This is a chronic,
inflammatory intestinal immune disease in ruminants (predominantly
bovines, sheep & deer) which is caused by an infection with
Mycobacterium avium subspecies paratuberculosis (MAP).
In New Zealand alone, milk production losses caused by Johne’s disease is estimated at over USD$50 million annually.
The alpha trial results are expected to confirm that with multiple
Johne's disease biomarkers, the Pictor test will enable subclinical
detection and, consequently, more informed and effective livestock
management and improved production yields both in New Zealand and
globally.
Want to know more?
An Information Memorandum, an investor slide deck, and a subscription agreement are all available for intending investors.
So if you’re interested in investing, or would like more information, reply to this email, or give me a call on +64 21 902 901.
..................................................................................................
The above investment is not an offer of financial products that
requires disclosure under the Financial Markets Conduct Act 2013 (Act)
and is available only to wholesale investors as defined by that Act. It
is intended for distribution only to selected people to whom, under the
relevant laws, it can be lawfully distributed. It cannot be distributed
in any other jurisdiction, or to any other people. It is not an offer or
solicitations in any jurisdiction in which such offers or solicitations
are not authorised, or in which the person making such offers or
solicitations are not qualified to do so, or to any person to whom it is
unlawful to make such offers or solicitations. Any representation to
the contrary would be unlawful. No action has been taken by any person
that would permit a public offering in any jurisdiction where action for
that purpose would be required.
Cheers
John Paine B.Sc., Dip BIA
TBK Capital Limited
Level 10,120 Albert Street
Auckland 1010, New Zealand
Phone +64 9 307 3257
Mobile +64 21 902 901
Email john.paine@tbkcapital.co.nz
For more information, please click the contact button below to send us a message.
⇑ back to top